Short Interest in Invivyd, Inc. (NASDAQ:IVVD) Expands By 15.8%

Invivyd, Inc. (NASDAQ:IVVD) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 8,270,000 shares, a growth of 15.8% from the October 15th total of 7,140,000 shares. Currently, 11.4% of the shares of the company are short sold. Based on an average trading volume of 463,300 shares, the days-to-cover ratio is currently 17.9 days.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Invivyd in a research report on Tuesday, October 29th. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th.

Institutional Investors Weigh In On Invivyd

Institutional investors and hedge funds have recently bought and sold shares of the business. Proficio Capital Partners LLC acquired a new position in shares of Invivyd during the third quarter valued at approximately $27,000. XTX Topco Ltd grew its stake in Invivyd by 68.1% in the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock valued at $42,000 after buying an additional 15,376 shares during the last quarter. SG Americas Securities LLC increased its position in Invivyd by 198.6% in the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after buying an additional 25,201 shares during the period. Cornercap Investment Counsel Inc. acquired a new position in Invivyd during the 2nd quarter valued at $86,000. Finally, Rhumbline Advisers raised its holdings in Invivyd by 4,434.1% in the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock valued at $92,000 after acquiring an additional 82,164 shares in the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Trading Down 4.5 %

Invivyd stock opened at $0.76 on Monday. The stock has a market cap of $90.19 million, a P/E ratio of -0.39 and a beta of 0.65. The stock has a 50 day moving average of $0.99 and a 200-day moving average of $1.28. Invivyd has a 52 week low of $0.76 and a 52 week high of $5.20.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.